Back

VICTORION IMPLEMENT: an observational study of the lipid management landscape in Germany

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Drug therapy (2) Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Oliver Weingaertner

University hospital Jena, Jena (Germany)

6 More presentations in this session

Presentation thumbnail
Bempedoic acid in clinical practice.
Doctor J. Vazquez Reguera (Las Palmas de Gran Canaria, ES)
Abstract Slides Video
Presentation thumbnail
Association of lipid-lowering drug treatment with all-cause and cardiovascular mortality among people aged 75 years and above without cardiovascular disease: evidence from a cohort study
Assistant Professor Z. Yang (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis
Doctor C. Bonanad Lozano (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
LDL on target - strike early and strike strong... just strike...
Doctor L. Hamann (Faro, PT)
Abstract Slides Video
Presentation thumbnail
Analytical approaches to open label extension (OLE) after cardiovascular outocmes trials: Observations from the FOURIER and FOURIER-OLE trials
Doctor H. Wang (Newbury Park, US)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Lipid-lowering therapy with Inclisiran in the real-world setting: initial data from a national health care service
thumbnail
Congress Presentation
Low-density lipoprotein cholesterol goal attainment with "inclisiran first" versus usual care in patients with atherosclerotic cardiovascular disease
thumbnail
Congress Presentation
Real-world prescribing patterns for lipid-lowering therapy in high cardiovascular risk patients in germany: a cross-sectional analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources